interferon – Page 44 – Communicable Diseases Research

Defining the Innate Immune Responses for SARS-CoV-2-Human Macrophage Interactions

SARS-CoV-2-인간 대식세포 상호작용에 대한 타고난 면역 반응 정의

Immunology

Published on 2021-10-042022-09-11
Journal: Frontiers in Immunology [Category] MERS, SARS, 유전자 메커니즘,

The early interferon catches the SARS-CoV-2

초기 인터페론은 SARS-CoV-2를 잡습니다.

Comment

Published on 2021-10-042022-09-11
Journal: The Journal of Experimental Medicine [Category] SARS, 치료제,

[키워드] Antiviral Biomarker Biomarkers epithelial cell epithelial cells Exp growth Infection inhibit SARS-CoV-2 innate antiviral immunity interferon interferons mucosa mucosal nasopharyngeal the SARS-CoV-2
[DOI] 10.1084/jem.20211667 PMC 바로가기 [Article Type] Comment

Hamster organotypic modeling of SARS-CoV-2 lung and brainstem infection

Article

Published on 2021-10-042022-10-04
Journal: Nature Communications [Category] SARS, 유전자 메커니즘, 치료제,

A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study

PD-1/PD-L1 억제제로 치료받은 암 환자를 대상으로 한 BNT162b2 항-SARS-CoV-2 백신 전체 과정의 면역원성, 효능 및 안전성에 대한 스냅샷: 종단적 코호트 연구

Article

Published on 2021-10-012022-09-11
Journal: ESMO open [Category] MERS, SARS, 바이오마커, 진단,

[키워드] 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adaptive administration anti-SARS-CoV-2 blood sample Blood samples BNT162b2 BNT162b2 anti-SARS-CoV-2 vaccine BNT162b2 vaccine Cancer cancer patient Cancer patients CD4 CD4+ CD4+ T follicular response CD8+ T-cell CD8+ T-cell response cell-mediated immune cellular response Complete coronavirus coronavirus disease coronavirus disease-2019 Course COVID-19 case COVID-19 cases demonstrated Efficacy and safety elicit elicited enrolled enzyme enzyme-linked immunospot assay Focusing follicular humoral IFN-γ Immune checkpoint inhibitors immune response inhibitor interferon interferon-γ interquartile range IQR knowledge longitudinal cohort study mandatory median Messenger RNA mononuclear cell naïve naïve subjects Neutralizing antibodies no difference no differences of BNT162b2 participant Patient patients PBMC PD-1/PD-L1 inhibitors Peripheral blood primary endpoint programmed cell death programmed cell death protein proportion Protein reached reported respiratory response SARS-CoV-2 SARS-CoV-2 neutralizing antibodies SARS-CoV-2 neutralizing antibody second dose severe acute respiratory syndrome Coronavirus significant increase significantly higher significantly increased Specific T-cell response spike-specific T-cell response subject subjects sustained T cells T-cell Response the primary endpoint treated undetectable vaccination vaccination schedule Vaccine
[DOI] 10.1016/j.esmoop.2021.100272 PMC 바로가기 [Article Type] Article

Discrimination of COVID-19 From Inflammation-Induced Cytokine Storm Syndromes Using Disease-Related Blood Biomarkers

질병 관련 혈액 바이오마커를 사용한 염증 유발 사이토카인 폭풍 증후군과 COVID-19의 구별

Article

Published on 2021-10-012022-09-11
Journal: Arthritis & rheumatology (Hoboken, N.J.) [Category] 바이오마커,

[키워드] Activation Adhesion Molecule association Biomarker Biomarkers Characteristics classic condition correlation correlations Course COVID-19 Critical cytokine Cytokine storm discrimination disease drugs targeting dysregulation Efficacy enzyme-linked immunosorbent enzyme-linked immunosorbent assay healthy control healthy controls hemophagocytic lymphohistiocytosis high mortality HLH hyperinflammation IL-1 IL-1 receptor antagonist IL-8 immune activation immune dysregulation intercellular intercellular adhesion molecule interferon interleukin Interleukin-18 Level longitudinal samples Macrophage macrophage activation syndrome measurement Novel coronavirus novel coronavirus SARS-CoV-2 observation occur outcome pathway Pathways Patient patients patients with COVID-19 performed profile quantified receptor antagonist reduced SARS-COV-2 infection secondary hemophagocytic lymphohistiocytosis Serum level serum levels serum sample serum samples severe COVID-19 soluble Fas ligand storm subgroup of patients systemic cytokine systemic hyperinflammation thought Treatment treatment of COVID-19 Trigger triggers were assessed
[DOI] 10.1002/art.41763 PMC 바로가기 [Article Type] Article

Insight into the emerging role of SARS-CoV-2 nonstructural and accessory proteins in modulation of multiple mechanisms of host innate defense

숙주 선천적 방어의 다중 메커니즘의 조절에서 SARS-COV-2 비 구조 및 보조 단백질의 새로운 역할에 대한 통찰력

Review

Published on 2021-10-012022-09-01
Journal: Bosnian Journal of Basic Medical Sciences [Category] 진단,

[키워드] accessory protein accessory proteins Activation acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition Antigen presentation Apoptosis array caused complex coronavirus coronavirus disease Coronavirus disease-19 COVID-19 Defense disease severity disrupting effector molecules Elimination ENhance favor Frame Health Host host immune system IFN-I IFN-I signaling immune evasion immune response immunomodulators Infection Infectious disease Inflammatory mediators insight interferon mediators modulate modulation molecular multiple mechanism nonstructural protein nonstructural proteins Nsps ORFs pathogenic pathway persistence proinflammatory respiratory SARS-CoV-2 SARS-COV-2 infection severe acute respiratory syndrome Coronavirus Signaling Therapies therapy type I interferon Vaccine Viral viral adaptation virus
[DOI] 10.17305/bjbms.2020.5543 PMC 바로가기 [Article Type] Review

Efficacy and safety of pegylated interferon-α2b in moderate COVID-19: a phase 3, randomized, comparator-controlled, open-label study

중등도 COVID-19에서 페길화된 인터페론-α2b의 효능 및 안전성: 3상, 무작위, 비교 대조, 공개 라벨 연구

Clinical Trial

Published on 2021-10-012022-09-11
Journal: International Journal of Infectious Diseases [Category] SARS, 바이오마커, 임상, 치료제,

[키워드] 1:1 acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 Administered adult subject adult subjects alpha-2b Arm ARMS Biomarker Biomarkers clinical status clinically conjunction coronavirus disease Coronavirus disease-19 Coronavirus-2 COVID-19 Day decrease Efficacy and safety evaluate Health Organization IFN IFN-α2b interferon interferon alpha-2b Laboratory parameters limit moderate Moderate COVID-19 Moderate subjects Open-label Ordinal Scale oxygen Pegylated interferon alpha-2b (PEG IFN-α2b) phase Phase 3 primary endpoint proportion provide Randomized receive safety profile SARS-CoV-2 seven-point ordinal scale severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus-2 significant changes in Spread Standard of care subject subjects supplemental oxygen viable treatment viral clearance World Health Organization
[DOI] 10.1016/j.ijid.2021.08.044 PMC 바로가기 [Article Type] Clinical Trial

T-cell responses to SARS-CoV-2 in multiple sclerosis patients treated with ocrelizumab healed from COVID-19 with absent or low anti-spike antibody titers

코로나19에서 치유된 오크렐리주맙 치료를 받은 다발성 경화증 환자의 SARS-CoV-2에 대한 T-세포 반응

Article

Published on 2021-10-012022-09-11
Journal: Multiple sclerosis and related disorders [Category] MERS, 진단, 치료법,

[키워드] abrogate absence acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 anti-S anti-SARS-CoV-2 antibody anti-spike antibody antibodies approach B-cell CD20 CD4/CD8 Concentration Coronavirus-2 COVID-19 depleting detect detectable diagnostic Disease modifying therapies domain enrolled FIVE glycoprotein IGRA immune response immunodominant Immunological response impair IMPROVE interferon Interferon-gamma multiple sclerosis natural infection not affect Nucleocapsid phosphoprotein Ocrelizumab Patient patients patients treated peptide peptides Peripheral blood receiving reduce reduction respiratory SARS-CoV-2 SARS-COV-2 infection sequence Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus Specific T-cell response spike glycoprotein Stimulation subset T-cell Response T-cell responses T-lymphocyte T-lymphocyte, peptides. the Spike therapy Treatment vaccination Whole blood
[DOI] 10.1016/j.msard.2021.103157 PMC 바로가기 [Article Type] Article

Insight into the emerging role of SARS-CoV-2 nonstructural and accessory proteins in modulation of multiple mechanisms of host innate defense

Review

Published on 2021-10-012022-10-27
Journal: Bosnian Journal of Basic Medical Sciences [Category] COVID-19,

[키워드] accessory protein accessory proteins Activation acute respiratory syndrome addition Antigen presentation Apoptosis caused complex coronavirus COVID-19 Defense disease severity disrupting effector molecules ENhance favor Frame Health Host host immune system IFN-I IFN-I signaling immune evasion immune response immunomodulators Infection Infectious disease Inflammatory mediators insight interferon modulate modulation molecular multiple mechanism nonstructural protein nonstructural proteins ORFs pathogenic pathway persistence proinflammatory SARS-CoV-2 SARS-COV-2 infection Signaling Therapies therapy type I interferon Vaccine viral adaptation virus
[DOI] 10.17305/bjbms.2020.5543 PMC 바로가기 [Article Type] Review

The ROMANOV study found impaired humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in virus-unexposed patients receiving maintenance hemodialysis

ROMANOV 연구는 유지 혈액투석을 받고 있는 바이러스에 노출되지 않은 환자에서 SARS-CoV-2 mRNA 백신에 대한 손상된 체액 및 세포 면역 반응을 발견했습니다

Article

Published on 2021-10-012022-09-12
Journal: Kidney international [Category] MERS, SARS, 진단,

[키워드] absence Analysis Anti-RBD IgG Anti-spike benefit BNT162b2 CD4 CD8 Cell Cellular immune response circulation Complete correlated COVID-19 COVID-19 in patient death dose effector generate healthy volunteer healthy volunteers Hemodialysis high risk humoral IgG immune immune response immune responses immunosuppressive Infection injection interferon less mRNA vaccine mRNA vaccines naïve of BNT162b2 Patient RBD receiving Receptor binding domain SARS-CoV-2 SARS-CoV-2 virus significantly T cell T cells therapy vaccination Vaccine vaccine injection virus weakened were excluded were measured
[DOI] 10.1016/j.kint.2021.07.005 PMC 바로가기 [Article Type] Article